Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2013)
Fate Therapeutics (FATE) posted Gains from Investment Securities of $29000.0 for Q4 2013, up 193.55% on a QoQ basis from -$31000.0 in Q3 2013, and up 1550.0% year-over-year from $1757.6 in Q4 2012.
Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2013) Analysis & Trends
Fate Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $29000.0 for Q4 2013.
- Quarterly Gains from Investment Securities rose 1550.0% year-over-year to $29000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2017 was $20000.0 (changed N/A YoY) and the FY2017 annual result came in at $30000.0, changed N/A from the prior year.
- Gains from Investment Securities was $29000.0 for Q4 2013 at Fate Therapeutics, up from -$31000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $29000.0 in Q4 2013 and bottomed at -$31000.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 29,000.00 |
| Dec 31, 2013 | 29,000.00 |
| Sep 30, 2013 | -31,000.00 |
| Sep 30, 2013 | -31,000.00 |
| Jun 30, 2013 | 22,000.00 |
| Jun 30, 2013 | 22,000.00 |
| Mar 31, 2013 | -12,000.00 |
| Mar 31, 2013 | -12,000.00 |
| Dec 31, 2012 | -2,000.00 |
| Dec 31, 2012 | -2,000.00 |